Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
880kB
[img] Other (Supplementary Data)
153kB

Item Type:Article
Title:Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis
Creators Name:Abrahamyan, S. and Eberspächer, B. and Hoshi, M.M. and Aly, L. and Luessi, F. and Groppa, S. and Klotz, L. and Meuth, S.G. and Schroeder, C. and Grüter, T. and Tackenberg, B. and Paul, F. and Then-Bergh, F. and Kümpfel, T. and Weber, F. and Stangel, M. and Bayas, A. and Wildemann, B. and Heesen, C. and Zettl, U. and Warnke, C. and Antony, G. and Hessler, N. and Wiendl, H. and Bittner, S. and Hemmer, B. and Gold, R. and Salmen, A. and Ruprecht, K.
Abstract:OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS). METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany. RESULTS: EBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts. CONCLUSION: The complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS.
Source:Journal of Neurology Neurosurgery and Psychiatry
ISSN:0022-3050
Publisher:BMJ Publishing Group
Volume:91
Number:7
Page Range:681-686
Date:July 2020
Official Publication:https://doi.org/10.1136/jnnp-2020-322941
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library